Study of Cognitive Symptoms and Future Time Perspective in Preclinical Alzheimer's Disease

我是一名临床心理学家和研究员，克拉克学者， 宾夕法尼亚大学的精神病学。我研究性和性别在阿尔茨海默病(AD)和有前途的 阿尔茨海默病的诊断和治疗取得了进展。研究人员假设阿尔茨海默病有一个阶段，称为“临床前” AD，“定义为个体认知没有受损，但有AD的生物标志物证据的情况。 将来，临床前阿尔茨海默病患者将得到处方治疗和其他干预措施，以延迟或减缓 疾病的发展。可能需要什么干预措施以及这些干预措施可能需要如何 设计的关键是了解临床前AD的体验，以及这种体验可能会如何变化 关于性别和其他社会文化因素。 我研究了AD研究参与者在认知能力下降的连续统一体中的经历 未受损至中度认知受损，以了解可能的心理护理类型 需要支持将这一预防阿尔茨海默病模式转化为常规做法。在家长奖中，我是 研究临床前阿尔茨海默病患者生活体验的两个核心特征：主观认知抱怨 (SCCS)和未来时间透视(FTP)。我正在研究一个人对他们的AD生物标记物的了解 结果，特别是淀粉样蛋白PET扫描结果，a)影响他们的SCC和FTP，b)与SCC的报告相互作用 以及AD的病理措施，以及c)ftp的变化如何影响决策。来自家长的调查结果 研究将展示SCC和FTP在临床前AD体验中的表现。 我建议，扩大父母的研究，以表征性别对SCC、FTP和决策的影响- 在临床前AD的经历中。这一点很重要，因为个人对不确定性的反应方式， 报告 在自我认同的男人和女人中 根据他们的记忆，以及对他们未来的规划，男性和女性可能会有所不同。 检视 我 将要 进行一系列研究 性别是如何通过队列差异衡量的， 沉默的婴儿潮世代-与a)AD生物标记物知识和SCC之间的关联，b) 鳞状细胞癌的报告和AD病理的测量，以及c)ftp和决策之间的联系。什么 我 研究人员可以将其用作SCC 过渡时期 发展保护健康的干预措施，如ftp 了解性别在临床前AD体验中的作用将为临床医生提供新的数据 目前用于对临床前AD的第二阶段进行分类，这是一种截然不同的 介于无症状(阶段1)和轻度受损(阶段3)之间的阶段。 预测个人的决策，例如 其次，调查结果将为 健康和财务规划行为。了解性别如何影响SCC和FTP的行为方式 临床前AD的经验将确保临床前AD的成功翻译和预防模式 它将伴随着从研究到实践的过程。这个项目将为我提供竞争所需的试验数据 用于R01资金。

I'm a clinical psychologist and researcher, Clark Scholar, and Assistant Professor in the Department of Psychiatry at University of Pennsylvania. I study sex and gender in Alzheimer's disease (AD) and the promising advances being made in the diagnosis and treatment of AD. Researchers posit a stage of AD called “Preclinical AD,” defined as a condition in which individuals are cognitively unimpaired but have biomarker evidence of AD. In the future, persons with Preclinical AD will be prescribed therapies and other interventions to delay or slow the disease progression. What interventions may be needed and how those interventions might need to be designed hinges on understanding the experience of Preclinical AD, and how that experience might vary based on gender and other sociocultural factors. I study the experiences of AD research participants across the continuum of cognitive decline from unimpaired to moderately cognitively impaired in order to understand what types of psychological care may be needed to support the translation of this model of AD prevention into routine practice. In the parent award I am studying two features central to the experience of living with Preclinical AD: Subjective Cognitive Complaints (SCCs) and Future Time Perspective (FTP). I am examining how a person's knowledge of their AD biomarker result, specifically an amyloid PET scan result, a) affects their SCCs and FTP, b) interacts with reports of SCCs and measures of AD pathology, and c) how changes in FTP affect decision-making. Findings from the parent study will show how SCCs and FTP behave in the Preclinical AD experience. I propose, expanding the parent study, to characterize the influences of gender on SCC, FTP, and decision- making in the Preclinical AD experience. This is important to know as the ways individuals react to uncertainty, report in self-identified men and women on their memory, and plan for their futures can vary for men and women. to examine I will conduct a series of studies how gender – measured via cohort differences in the Greatest, Silent, Boomer Generations – interacts with a) associations between AD biomarker knowledge and SCCs, b) reports of SCCs and measures of AD pathology, and c) associations between FTP and decision-making. What I and researchers can use as SCCs transitional development of interventions that protect wellbeing as FTP discover about how gender operates in the Preclinical AD experience will offer novel data t hat, first, clinicians are currently used to classify stage 2 of Preclinical AD, which is a distinct stage between asymptomatic (stage 1) and mildly impaired (stage 3). predicts an individual's decision-making, such as Second, findings will inform healthand financial planning behaviors. Discovering how gender influences the ways SCCs and FTP behave in the Preclinical AD experience will assure successful translation of Preclinical AD and the model of prevention in AD that it will accompany from research into practice. This project will give me the pilot data I need to compete for R01 funding.